An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday.
Original Article: Amgen drug shrinks lung cancer tumors in half of patients: study